One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field

One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field

Source: 
Endpoints
snippet: 

You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe
Already a paid subscriber? Sign in to Endpoints News to remove this message.

As head of the Center for Human Genetic Research at Massachusetts General Hospital and the Broad’s Cardiovascular Disease Initiative, Sekar Kathiresan has occupied a singular position as one of the world’s leading experts on the connection between genetics and coronary heart disease. He’s tracked how people dealt a bad genetic hand — and the elevated risks that come with it — can limit inherent dangers by lifestyle changes, and pondered over the effects of daily drugs used to treat mass patient groups. And he’s reached a simple conclusion:

None of it is really working.